Références
1) Linssen GC, Bakker SJ, Voors AA, Gansevoort RT, Hillege HL, de Jong PE, et al. N-terminal pro-B-type natriuretic
peptide is an independent predictor of cardiovascular morbidity and mortality in the general population. Eur Heart J
2010 ; 31 : 120-7
2) Hill SA, Balion CM, Santaguida P, McQueen MJ, Ismaila AS, Reichert SM et al. Evidence for the use of B-type
natriuretic peptides for screening asymptomic populations and for diagnosis in primary care. Clin Biochem 2008 ;
41 : 240-9
3) Zaphiriou A, Robb S, Murray-Thomas T, Mendez G, Fox K, McDonagh T., et al. The diagnosis accuracy of plasma BNP
and NTproBNP in patients referred from primary care with suspected heart failure : results of the UK natriuretic
peptide study. Eur J Heart Fail 2005 ; 11 : 537 - 41
4) Gustafsson F, Steensgaard-Hansen F, Badskjaer J, Poulsen AH, Corell, Hilldebrandt P. Diagnostic and prognostic
performance of N-Terminal ProBNP in primary care patients with suspected heart failure. J Cardiac Fail 2005 ; 11 :
S15 – S20
5) Rosenberg J, Schou M, Gustafsson F, Badskjaer, Hilldebrandt P. Prognostic threshold levels of NT-proBNP testing in
primary care. Eur Heart J 2009 ; 30 : 66 – 73
6) Hilldebrandt P, Collinson PO, Doughty RN, Fuat A, Gaze DC, Gustafsson F, et al. Age-dependent values of N-Terminal
pro-B-type natriuretic peptide are superior to a single cut-point for ruling out suspected systolic dysfunction in
primary care. Eur Heart J 2010 ; doi :10.1093/eurheartj/ehq163
7) Masson S, Latini R, Anand IS, Vago T, Angelicini L, Barlera S, et al on behalf of the Val-HeFT Investigators. Direct
comparison of B-Type Natriuretic Peptide (BNP) and Amino-Terminal proBNP in a large population of patients with
chronic and symptomatic heart failure : the Valsartan Heart Failure (Val-HeFT) Data. Clin Chem 2006 ; 52 : 1528-38
8) Masson S, Latini R, Anand IS, Barlera S, Angelicini L, Vago T, et al, for the Val-HeFT Investigators. Prognostic value of
changes in N-Terminal Pro-Brain Natriuretic Peptide in Val-HeFT (Valsartan Heart Failure Trial). J Am Coll Cardiol
2008 ; 52 : 997 – 1003
9) Kuban M, Goode KM, Lanska V, Clark AL, Cleland JGF. The prognostic value of repeated measurement of N-terminal
pro-B-type natriuretic peptide in patients with chronic heart failure due to left ventricular systolic dysfunction. Eur J
Heart Fail 2009 ; 11 : 367 – 77
10) Bhardwaj A, Rehman S, Mohammed A, Baggish AL, Moore SA, Januzzi JL. Design and methods of the Pro-B Type
Natriuretic Peptide Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study. Am Heart J 2010 ; 159 :
532 – 38
11) Porapakkham Pr, Porapakkham Po, Zimmet H, Billak B, Krum H. B-Type Natriuretic Peptide guided heart failure
therapy. A meta-analysis. Arch Intern Med 2010 ; 170 (6) : 507 – 14
12) Felker GM, Hasselblad V, Hernandez AF, O’Connor CM. Biomarker-guided therapy in chronic heart failure : a meta-
analysis of randomized controlled trials. Am Heart J 2009 ; 158 : 422 - 30